8.16.18

8.6.18

CHARCOT-MARIE-TOOTH NEWS: REGENACY PARTNERS WITH CMTA TO ADVANCE DEVELOPMENT OF RICOLINOSTAT FOR TREATING CMT

Regenacy is partnering with the Charcot-Marie-Tooth Association (CMTA) to help develop the investigative therapy ricolinostat and evaluate its potential for CMT in animal models. The collaboration is expected to speed the advancement of the treatment candidate for clinical trials in CMT patients. READ MORE

8.2.18

PRESS RELEASE: REGENACY PHARMACEUTICALS ANNOUNCES COLLABORATION WITH THE CHARCOT-MARIE-TOOTH ASSOCIATION (CMTA) TO ADVANCE RICOLINOSTAT FOR THE TREATMENT OF HEREDITARY NEUROPATHY

7.26.17

A compound that blocks the activity of so-called HDAC enzymes in the brain improved learning in mouse models of Alzheimer’s disease, according to data that Regenacy Pharmaceuticals presented at the recent 2017 Alzheimer’s Association International Conference (AAIC) July 16-20 in London. READ MORE

PRESS RELEASE: REGENACY PHARMACEUTICALS TO BE LAUNCHED BY ACETYLON PHARMACEUTICALS AND CELGENE CORPORATION AGREES TO COMPLETE ACQUISITION OF ACETYLON

12.2.16

Earlier this year, Celgene passed on an exclusive option to buy Acetylon Pharmaceuticals. But surprisingly, the two companies have come up with a new deal instead. Celgene agreed Friday to acquire just a portion of the assets of the Boston company, which will spin the rest of its assets into a new startup called Regenacy Pharmaceuticals. READ MORE